Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review

Yong, Jie Ning; Lim, Wen Hui; Ng, Cheng Han; Tan, Darren Jun Hao; Xiao, Jieling; Tay, Phoebe Wen Lin; Lin, Snow Yunni; Syn, Nicholas; Chew, Nicholas; Nah, Benjamin; Dan, Yock Young; Huang, Daniel Q.; Tan, Eunice Xiang Xuan; Sanyal, Arun J.; Noureddin, Mazen; Siddiqui, Mohammad Shadab; Muthiah, Mark

doi:10.1016/j.cgh.2021.11.014

Cited by 32 publications

(38 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated a good 1-, 5-and 10-years post-transplant survival of 86%, 73% and 60%, respectively. These data are consistent with those recently published in a systematic review in this field [24]. A relevant number of patients died of sepsis (7) and of cardiovascular accidents (4); these two conditions accounted for half of all deaths in the post-transplant follow-up.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Non-alcoholic steatohepatitis (NASH) has become the leading indication for liver transplantation in many countries, with a growing rate in the Western world. NASH patients are older and share a higher risk of comorbidities and cancer than patients with viral and/or alcoholic etiologies. The aims of this study were to evaluate waiting list (WL) registration and liver transplantation rates in patients with NASH-related cirrhosis at Padua University Hospital in the last fifteen years (1.2006–6.2020) and to compare clinical characteristics and indications for liver transplantation between patients with and without NASH, as well as the WL survival and post-transplant outcome. Materials and Methods: All adult patients with cirrhosis listed for liver transplantation at Padua University Hospital between 1.2006 and 6.2020 were retrospectively collected using a prospectively updated database; patients with NASH-related cirrhosis were divided by indication for liver transplantation (Dec-NASH vs. hepatocellular carcinoma (HCC)-NASH) and compared with patients with other etiologies of liver disease. The outcomes in terms of waiting list survival and post-transplant outcome were assessed. Results: One thousand four hundred and ninety-one adult cirrhotic patients were waitlisted during the study period. NASH patients accounted for 12% of all WL registrations, showing an increasing trend over time (from 2.5% in 2006 to 23% in 2020). In the last five years, NASH was the third, but most rapidly growing, indication for liver transplantation at our center. This trend was confirmed both for patients with decompensated cirrhosis (from 1.8% to 18%) and HCC as leading indication for transplantation (from 4% to 30%). NASH patients were older than non-NASH ones (mean ± SD age 59 ± 9 vs. 56 ± 9 years; p < 0.01), whereas no difference was found in gender or Child-Pugh of the model for end-stage liver disease score at WL registration. A majority (60.9%) of NASH patients underwent liver transplantation, showing 1-, 5- and 10-y post-transplant survivals of 86%, 73% and 60%, respectively. Conclusion: NASH cirrhosis has become a rapidly growing indication for liver transplantation at our center, both for HCC and decompensated disease, with good post-transplant survival.

show abstract

Section: Discussionsupporting

confidence: 90%

“…A relevant number of patients died of sepsis (7) and of cardiovascular accidents (4); these two conditions accounted for half of all deaths in the post-transplant follow-up. Indeed, NASH confers a twofold higher risk of post-transplant death for sepsis and cardiovascular accidents, according to the recently published data [24].…”

Section: Discussionmentioning

confidence: 99%

Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Interestingly, in Yong and colleagues’ meta-regression of post-LT survival in NASH vs. non-NASH cohorts, they did not identify age as a predictor. 31 This may be explained by major differences between study populations, as the previous review only included NASH vs. non-NASH cohorts to analyze their primary survival outcome and conducted a meta-regression of the NASH subgroup as a secondary outcome. Furthermore, it was unclear whether the meta-regression adjusted for confounding variables that are associated with increased age (e.g., DM, dyslipidemia, chronic kidney disease), which the studies included in our review preformed.…”

Section: Discussionmentioning

confidence: 99%

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

“…They concluded that patients undergoing LT for NASH have comparable complication, overall survival, and graft survival rates compared with non-NASH patients, although close monitoring may be indicated for those with higher MELD scores. 61…”

Section: Liver Transplantation (Table 2)mentioning

confidence: 99%

“…Yong and colleagues conducted a systematic review to analyze time-dependent survival between LT recipients with and without NASH. 61 Fifteen studies involving 119,327 LT recipients were included in the analysis with a NASH prevalence of 20.2% (95% CI, 12.9-30.2). The pooled 1-year, 5-year, and 10-year all-cause mortality in NASH patients after LT were 12.5, 24.4, and 37.9%, respectively.…”

Section: Liver Transplantation (Table 2)mentioning

confidence: 99%

Abdominal Organ Transplantation: Noteworthy Literature in 2021

Jules

Blech

Sakai

2022

Semin Cardiothorac Vasc Anesth

View full text Add to dashboard Cite

This review highlights noteworthy literature pertinent to anesthesiologists and critical care physicians caring for patients undergoing abdominal organ transplantation. In 2021, we identified noteworthy papers from over 1,200 peer-reviewed publications on pancreatic transplantation, over 1,400 on intestinal transplantation, and over 9,000 on kidney transplantation. The liver transplantation section focuses on clinical trials and systematic reviews and meta-analyses published in 2021 and features 20 selected papers. COVID-19 and abdominal organ transplantation are featured in an independent section.

show abstract

Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review

Cited by 32 publications

References 59 publications

Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy

Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis

Abdominal Organ Transplantation: Noteworthy Literature in 2021

Contact Info

Product

Resources

About